Pharmafile Logo
Pharmafocus logo
Advanced Search

Glivec

Showing 15 posts of 22 posts found.

Lilly image

Lilly and Novartis face legal challenges

June 25, 2015
Medical Communications, Sales and Marketing Gleevec, Glivec, Novartis, cymbalta, imatinib, lilly, zyprexa

Judges in California have ruled that Lilly should face claims it failed to fully disclose the extent of post-withdrawal side …

News
Glivec image

Novartis cancer drug beating path to NHS

October 17, 2014
Sales and Marketing GIST, Glivec, NHS, NICE, imatinib, uturn

NICE has issued final draft guidance recommending Novartis’s Glivec for up to three years in people who have had a …

News
Glivec image

NICE U-turn on cancer drug despite price increase

June 27, 2014
Sales and Marketing Cancer, Glivec, NHS, Novartis, gists

UK pricing watchdog NICE has performed a U-turn on Glivec (imatinib) by issuing new draft guidance recommending the drug, despite …

News

Novartis reports healthy profit

April 25, 2014
Sales and Marketing Afinitor, Gleevec, Glivec, Novartis, Q1, lilly

Multiple sclerosis drug Gilenya and cancer treatment Afinitor were among the biggest sellers for Novartis, as the Swiss company’s net …

News

Sales rise for Novartis

January 30, 2014
Sales and Marketing Gleevec, Glivec, Novartis, gilenya, q4, sales

Multiple sclerosis drug Gilenya, with sales rising 62% year-on-year to $1.9 billion, was one of the stars of last year …

News
fda_sign_web

Double approval for Pfizer cancer drugs

September 6, 2012
Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc

 Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …

News
Novartis image

Novartis’ Indian patent case delayed

August 23, 2012
Sales and Marketing Glivec, MSF, Novartis, generics

Novartis’ court case against the Indian government has been put on hold until next month. The case was suppose to …

News

Ariad files new blood cancer drug with the FDA

July 31, 2012
Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer

Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …

News
Bayer image

Bayer cancer drug meets Phase III goal

April 3, 2012
Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib

Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …

News
Novartis image

Novartis Indian patent battle nears conclusion

March 7, 2012
Sales and Marketing Glivec, HIV, India, Novartis, patents

A long-running battle over the patent of cancer treatment Glivec in India is about to reach its dramatic climax.India’s Supreme …

News
Glivec

Glivec cleared for longer use in GIST patients

February 28, 2012
Sales and Marketing Europe, GIST, Gleevec, Glivec, Novartis

Glivec has gained EU approval for extended use after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST).The drug …

News

NICE says yes to Tasigna for resistant disease

January 13, 2012
Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna

NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …

News
Glivec picture

NICE recommends two Novartis cancer treatments

December 6, 2011
Sales and Marketing Glivec, Novartis, Sprycel, Tasigna

Two of Novartis’ cancer drugs have been recommended by NICE for the first line treatment of chronic myeloid leukaemia (CML) …

News
Novartis

New discount persuades NICE to back Novartis’ Tasigna

August 18, 2011
Sales and Marketing Glivec, NICE, Sprycel, Tasigna

NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …

News

‘Weak’ evidence leads to NICE no for three leukaemia drugs

May 6, 2011
Sales and Marketing Glivec, NICE, Sprycel, Tasigna

NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025